Astrazeneca Pharma India Ltd
NSE: ASTRAZEN BSE: 506820
₹5957
+6.50 (0.11%)
Thu, 22 Oct 2026, 07:45 pm
Market Cap (in Cr)14717.5
PE Ratio87.80
Dividend0.61
Health Technology
Pharmaceuticals: Major
24.5KAstrazeneca Pharma India Ltd Company History
1979
- Company incorporated on July 11; Certificate of Commencement obtained November 6.
- Promoted jointly by Astra Pharmaceuticals AB, Sweden and IDL Chemicals Ltd.
1980
- Enters technical collaboration with Astra Pharmaceuticals AB, Sweden for know-how.
- Undertakes project for manufacture of basic drugs, formulations, fine and industrial chemicals at Yelahanka, Bangalore.
1982
- Issues shares: 2,000 to promoters; 24,98,000 at par; 6,43,235 each to Astra and IDL; 3,78,830 to Indian directors/shareholders/employees; 8,32,700 to public.
- Pharmaceuticals and chemicals plant commissioned in February.
1988
- Launches Sensorcaine, Theobric, Restomycin, Bromenyl, Febafen, Prostodin, Selopres, Betaloc Durules, Tripres, Sensorcaine Spinal, Bricanyl Nebulising Solution, Pulmicort Inhaler, Bricanyl Inhaler, Spacehaler.
- Plans in-house facilities for inhalation therapy and prostaglandin formulations.
1991
- Launches PIMIPROST prostaglandin for safe motherhood.
1992
- Launches Cerviprime Gel and Plendil; proposes launches of Ramace, Rhinocort, Imdur.
1994
- Launches Ramace, Imdur, Rhinocort.
1995
- Issues 2,500,000 bonus shares in 1:1 proportion.
1996
- Introduces jumbo packs of Pulmicort and Bricanyl inhalers, low dose aspirin, Imdur 30 mg.
1997
- Launches new products: Xylocaine Spray, Stop-it, Mimbid, Linctus-D, Rhinocort Aqua, Rejois, Cellubril.
- Establishes production facilities for aerosols and soft gelatin capsules.
- Astra-IDL joint venture faces prolonged litigation between promoters.
1998
- Astra-IDL receives Analyst Award from ICFAI.
- Astra had set up 100% research facility in Bangalore three years ago.
1999
- Hindujas seek new partners to replace AstraZeneca in Astra-IDL joint venture.
2000
- UB Bioteck ties up with Astra IDL to market anti-obesity nutraceutical.
- Appoints D.E. Udwadia as Chairman.
2001
- Crisil places 'FAA' rating on fixed deposit programme with positive watch.
- Astra Sweden acquires 51.50% equity, making company its subsidiary in AstraZeneca Group.
- Managing Director A.R. Hegde resigns.
- Company renamed AstraZeneca Pharma India Ltd; Lars Walan appointed MD effective April 2.
2002
- Ties up with Avestha for tuberculosis drug research.
- Makes open offer to acquire 43% stake in AstraZeneca Pharma India Ltd.
- Government approves FDI proposal increasing stake from 56.69% to 100% for Rs. 82 crore.
- Astra Pharma acquires 32,800 equity shares of AstraZeneca.
2003
- Astra Pharma and AstraZeneca jointly acquire less than 4% additional equity in AstraZeneca Pharma India Ltd.
- Tom McKillop inaugurates R&D centre in Bangalore for $40 million.
- Approaches government for Exclusive Marketing Rights for two new anti-cancer drugs.
- Board accepts resignation of Mr. J G Zetterberg effective May 2004.
2006
- AstraZeneca acquires Eli Lilly's Vancocin brand.
- Company splits share face value from Rs 10 to Rs 2.
2007
- Appoints Mr. Ruud Dobber as Director.
2010
- AstraZeneca and Bristol-Myers Squibb launch Onglyza (saxagliptin) for type 2 diabetes in India.
- Appoints Ms. Anita Zutshi as CFO.
2011
- AstraZeneca halts late-stage trial of Zibotentan for prostate cancer.
- Appoints Mr. Himanshu Agarwal as CFO.
2012
- AstraZeneca Excellence in Chemistry Awards 2011.
- AstraZeneca and Cellworks collaborate for tuberculosis treatment.
- AstraZeneca launches BRILINTA (ticagrelor) in India.
2013
- AstraZeneca to acquire Bristol-Myers Squibb's share of global diabetes alliance assets.
- AstraZeneca enters co-promotion agreement with Janssen in Japan for prostate cancer treatment.
2014
- FDA approves FARXIGA (dapagliflozin) for AstraZeneca and Bristol-Myers Squibb.
- AstraZeneca and MRC enter strategic collaboration for early drug discovery centre in Cambridge, UK.
- AstraZeneca and Roche announce partnership for companion diagnostic test for AZD9291.
- Company shifts registered office to Manyata Embassy Business Park, Bangalore.
2015
- AstraZeneca Pharma India Ltd and Dr Reddy’s Laboratories enter distribution agreement for saxagliptin and metformin combination for type 2 diabetes.
- AstraZeneca Pharma launches type-2 diabetes treatment drug.
- BRILIQUE (ticagrelor) receives positive EU CHMP opinion for extended heart attack treatment.
- AstraZeneca completes acquisition of ZS Pharma.
- AstraZeneca opens new manufacturing facility in Russia.
2017
- AstraZeneca Pharma receives import permission for inhaler powder.
- AstraZeneca Pharma receives approval for Osimertinib Tablet.
2018
- AstraZeneca Pharma India Ltd receives DCGI permission for Durvalumab.
2021
- AstraZeneca partners with DocOn to digitize healthcare clinics across India.
- AstraZeneca and Rajiv Gandhi Cancer Institute launch Project Chariot for CLL diagnosis and treatment.
- AstraZeneca launches Clinical Data and Insights division in India.
2022
- AstraZeneca Pharma receives CDSCO approval for Dapagliflozin tablets.
2023
- AstraZeneca inaugurates Centre of Excellence at Manipal Hospital Goa for severe asthma patients.
- AstraZeneca India partners with Roche Diagnostics India to improve breast cancer diagnostic testing.
- Government of Karnataka signs MoU with AstraZeneca India to accelerate lung cancer testing.
2024
- AstraZeneca Pharma India Ltd and Mankind Pharma Ltd announce collaboration for exclusive distribution of Symbicort in India.
- AstraZeneca India receives CDSCO approval for Durvalumab additional indication.
- AstraZeneca and Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru.
- AstraZeneca receives CDSCO approval to import and market Andexanet Alfa for critical bleeding conditions.
